Comparison of neutrophil-to-lymphocyte ratio and lactate-to-albumin ratio as predictive inflammatory markers for sepsis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational comparison of two blood‑based inflammatory markers (neutrophil/lymphocyte ratio and lactate/albumin ratio) measured in adults admitted to the ICU with lower respiratory tract infection and sepsis or septic shock by Sepsis‑3 criteria. Researchers will record these ratios on admission and link them to clinical outcomes including mortality and organ dysfunction, then compare sensitivity and specificity for outcome prediction. Patients with conditions that alter serum albumin (malnutrition, nephrotic syndrome, liver cirrhosis, prior intestinal resection) and those outside the 18–80 age range are excluded. The work is conducted at a single center (Ain Shams University Hospital, Abbassia, Cairo).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults with lower respiratory tract infection
* Confirmed septic patients (under the third international consensus definitions of sepsis and septic shock),
* Admitted to intensive care unit.
* Age (18-80) years.
* Both genders.

Exclusion Criteria:

* Age: \< 18 years old, \> 80 years old
* Patient refusal.
* Pregnancy.
* Malignancy.
* Pathology that could affect serum albumin concentrations prior to ICU admission as Malnutrition
* Nephrotic syndrome
* Liver Cirrhosis
* Intestinal resection surgeries

Where it's running

• Ain Shams university
  Cairo, Abbassia, Egypt Recruiting

Study contacts

• Study coordinator: Ahmed Gamal Ahmed, M.BB.CH,M.Sc
• Email: ahmed_gamal@med.asu.edu.eg
• Phone: 01141164417

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Multicenter group study of sepsis and ARDS in China

  This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.

  Recruiting at 24 sites Shanghai Zhongshan Hospital · Xiamen, Fujian and 23 other locations · NCT07863908

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.